Morgan Stanley raised the firm’s price target on Cardinal Health to $100 from $92 and keeps an Overweight rating on the shares. Cardinal Health raised its 2024 EPS guidance with expectations intact for continuing Core Pharma strength and an ongoing Medical turnaround, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAH:
- Cardinal Health price target raised to $101 from $93 at JPMorgan
- Cardinal Health price target raised to $90 from $88 at TD Cowen
- Cardinal Health price target raised to $108 from $107 at Baird
- Cardinal Health (NYSE:CAH) Stock Down Despite Positive Q4 Results
- Cardinal Health raisesFY24 EPS view to $6.50-$6.75 from $6.45-$6.70